CYRX
NASDAQ
US
CryoPort, Inc. - Common Stock
$8,77
▲ +$0,26
(+3,06%)
Vol 239K
12
Skor Kualitas
ok
Pendapatan ✗
Laba Bersih ✗
>IPO ✗
Kap. Pasar
$480.7M
P/E
7,1
ROE
14,8%
Margin
35,5%
D/E
36,50
Beta
1,66
52W
$5–$11
Konsensus Wall Street
16 analis · Apr 20266
Beli Kuat
8
Beli
2
Tahan
0
Jual
0
Jual Kuat
87,5%
Peringkat Beli
Grafik Harga
Saham Serupa
BLFS
BioLife Solutions Inc
$1.2B
FTRE
Fortrea Holdings Inc
$1.6B
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
PACB
Pacific Biosciences of California Inc
$564.6M
LAB
Standard BioTools Inc
$492.2M
OABI
OmniAb Inc
$266.3M
Pendapatan
Tingkat beat: 75,0%| Kuartal | EPS Estimasi | EPS Aktual | Kejutan |
|---|---|---|---|
| Des 2025 | $-0,21 | $-0,27 | $-0,06 |
| Sep 2025 | $-0,22 | $-0,18 | +$0,04 |
| Jun 2025 | $-0,24 | $2,05 | +$2,29 |
| Mar 2025 | $-0,32 | $-0,28 | +$0,04 |
Pendapatan & Laba Kuartalan
| Kuartal | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Pendapatan | — | $59.5M | $41.0M | $45.5M | $44.2M | $45.5M |
| Laba Bersih | — | -$18.7M | -$12.0M | $105.2M | -$6.9M | -$11.6M |
Tren Fundamental
| Metrik | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 17.4% | 17.4% | 17.4% | 17.4% | 14.8% | 14.8% |
| P/E (TTM) | 4.97 | 5.88 | 6.30 | 6.14 | 6.78 | 7.11 |
| Net Margin | 231.4% | 37.2% | 37.2% | 37.2% | 35.5% | 35.5% |
| Gross Margin | 47.0% | 45.7% | 45.7% | 45.7% | 46.6% | 46.6% |
| D/E Ratio | 36.32 | 36.32 | 36.32 | 36.32 | 36.50 | 36.50 |
| Current Ratio | 16.24 | 16.24 | 16.24 | 16.24 | 15.77 | 15.77 |
Rasio Utama
ROA (TTM)
9,2%
P/S (TTM)
2,53
P/B
1,0
EPS (TTM)
$1,34
CF/Share
$-0,59
Pertumbuhan Pendapatan 3T
+0,9%
52W High
$11,44
52W Low
$4,58
$4,58
Rentang 52 Minggu
$11,44
Kesehatan Keuangan
Arus Kas Bebas
-$4.0M
Utang Bersih
-$19.8M
Kas
$250.5M
Total Utang
$230.7M
Per tanggal Des 31, 2025
Як CYRX виглядає на тлі конкурентів у Life Sciences Tools & Services?
Група порівняння: Small-cap Life Sciences Tools & Services ($300M+) · 25 компаній
Оцінка CYRX vs аналоги Life Sciences Tools & Services
P/E
7,1
▼
78%
di bawah
rekan
(32,5)
vs Rekan
vs Industri
Undervalued
P/S
2,5
▼
34%
di bawah
rekan
(3,8)
vs Rekan
vs Industri
Undervalued
P/B
1,0
▼
74%
di bawah
rekan
(3,7)
vs Rekan
vs Industri
Undervalued
Дивідендна дохідність
—
▼
0%
di bawah
rekan
(0,5%)
vs Rekan
vs Industri
Yield rendah
Прибутковість CYRX vs аналоги Life Sciences Tools & Services
ROE
14,8%
▲
552%
di atas
rekan
(-3,3%)
vs Rekan
vs Industri
Tingkat atas
Net margin
35,5%
▲
478%
di atas
rekan
(-9,4%)
vs Rekan
vs Industri
Tingkat atas
Валова маржа
46,6%
▼
3%
di bawah
rekan
(48,0%)
vs Rekan
vs Industri
Lemah
ROA
9,2%
▲
452%
di atas
rekan
(-2,6%)
vs Rekan
vs Industri
Tingkat atas
Фінансове здоровʼя CYRX vs аналоги Life Sciences Tools & Services
D/E ratio
36,5
▼
0%
di bawah
rekan
(36,5)
vs Rekan
vs Industri
Sejajar
Поточна ліквідність
15,8
▲
367%
di atas
rekan
(3,4)
vs Rekan
vs Industri
Likuiditas kuat
Beta
1,7
▲
17%
di atas
rekan
(1,4)
vs Rekan
vs Industri
Lebih volatil
Радар фундаменталів CYRX
CYRX
Median rekan
Industri
CYRX прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CYRX vs аналоги: ключові метрики
Berita Terbaru
Belum ada berita terkait